Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year. The downturn pulled every major index ...

Yacktman Asset Management's Q3 2025 13F portfolio value declined to $7.26B, with 70 holdings and ~9% cash. Learn more about ...

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Fintel reports that on November 4, 2025, Evercore ISI Group downgraded their outlook for Kimberly-Clark (NasdaqGS:KMB) from ...

In this piece, we will look at the stocks Jim Cramer discussed.

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong ...